It's astounding the number of people suffering with CLBP, with the constant barrage of the stem cell keyboard samaritans telling us repeatedly how ineffective Mesoblast is and all this without disclosure of their interest in seeing Mesoblast fail.
Mesoblast move on from aGVHD for under 12 best to have a luke warm approach put the onus on the FDA and let them showcase their agenda. Full focus on CLBP is the way forward for Mesoblast. I do not believe Mesoblast will have any issues attracting funding through a CR or be prepared to give up a larger slice of the business to a partnership hopefully either Surgcentre or Pharma as this will put Mesoblast back on track and will minimise the rot being espoused.
rexlemestrocel-L in the treatment of chronic low back pain (CLBP), page-4
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |